Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pentheroudakis, G.
Right arrow Articles by Pavlidis, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pentheroudakis, G.
Right arrow Articles by Pavlidis, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:349-351, 2003
© 2003 European Society for Medical Oncology

Editorial

Immunomodulation in colorectal cancer: disappointment or promise?

G. Pentheroudakis and N. Pavlidis*

Department of Medical Oncology, Ioannina University Hospital, 45110 Ioannina, Greece

*E-mail: npavlid@cc.uoi.gr

The first 10% of the full text of this article appears below.

The treatment of patients with localised rectal carcinoma is a field of continuing debate as failure rates of 30–60% for Dukes’ B2 and C disease [1] indicate the need for optimal adjuvant therapy. Postoperative 5-FU-based chemoradiation is the standard of care [2] in the USA whereas the European approach ranges from adoption of the NIH Consensus Conference recommendations to focus on preoperative radiation or total mesorectal excision. Ongoing studies are likely to enlighten us with the optimal multimodality strategy. With the recent resurgence of interest in the interactions of the immune system and colorectal cancer, immunomodulation may well become part of such a therapy.

At the end of the 19th century William B. Coley, a New York surgeon, intentionally infected patients with metastatic solid tumours with heat-killed streptococci after he observed tumour regression in a patient with recurrent erysipelas. Surprisingly, he did obtain . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?